Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Joey Stringer - Needham & Company, LLC - Analyst : Great. Thank you, Terrie, for that overview. You provided a little bit on the history of the company, but I really think it helps set the stage for this entire story here. So for those of you who are not familiar with the story, can you give us a history for how Phathom was founded around the asset, vonoprazan?

Question: Joey Stringer - Needham & Company, LLC - Analyst : In terms of the economic obligation to Takeda, such as milestones, royalties around vonoprazan, can you touch on that? And can you also discuss Takeda's current financial interest in Phathom related to the license agreement such as warrants, et cetera?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Okay. Thank you, Molly. Getting back to vonoprazan, the mechanism of action here. Again, for some not as familiar with the story, what is unique about vonoprazan relative to, say, generic PPIs that are available?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Great. And you mentioned the Takecab launch in Japan generating $800 million-plus annual run rate sales. I'm just curious if you can compare and contrast the key similarities and even some of the differences between that market in Japan, and how that could translate to the -- what the market could look like in the US?

Question: Joey Stringer - Needham & Company, LLC - Analyst : And what's the breakdown of Takecab sales by indication in Japan, GERD and H. pylori, even on relative basis?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Okay. Thank you. Now we'll go on to more -- Phathom's vonoprazan results, and you announced positive results from the Phase 3 trial in erosive esophagitis last October. Can you review the key efficacy and safety data from this trial?

Question: Joey Stringer - Needham & Company, LLC - Analyst : No, sorry. Go ahead.

Question: Joey Stringer - Needham & Company, LLC - Analyst : And can you comment on the potential regulatory -- both the regulatory and commercial implications for this observed higher efficacy in the more severe EE patients, the grade C/D patients versus the grade A?

Question: Joey Stringer - Needham & Company, LLC - Analyst : And is there a key efficacy metric? You mentioned the speed of onset and the durability. Is there a key data point from the Phase 3 EE trial that it's most important to practicing physicians in the real world setting?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Yeah. And you had the recent NDA submission in EE. Can you describe what was included in that submission? And, again, just to reiterate your stance or your thoughts on what type of label you'll be seeking in EE?

Question: Joey Stringer - Needham & Company, LLC - Analyst : And how is the launch for EE? How is that launch prep progressing? What's been the key metrics here that you're monitoring? What's been the feedback from clinicians and KOLs around the data? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 12, 2022 / 1:30PM, PHAT.OQ - Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual)

Question: Joey Stringer - Needham & Company, LLC - Analyst : How should we think about pricing? What's a good comp for this in -- for vonoprazan in EE?

Question: Joey Stringer - Needham & Company, LLC - Analyst : And along the lines of the market access front here, what's your current thinking or what would a typical patient journey be like -- a patient with EE to get on commercial vonoprazan?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Thank you. That's a very helpful overview. And I don't want to forget about H. pylori. I know you have an upcoming PDUFA. So with the time remaining, we'll touch on H. pylori and also another program in NERD. But first of all, H. pylori, can you summarize the Phase 3 data key findings from that, and what type of label you'll be seeking in H. pylori?

Question: Joey Stringer - Needham & Company, LLC - Analyst : And what do you think the commercial opportunity in H. pylori is? What are some reasonable expectations for peak sales?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Yeah. Thanks. Very helpful overview of H. pylori. And certainly want to leave some time for the program in non-erosive reflux disease, NERD. You reported some Phase 2 results and you have a Phase 3 program ongoing. Can you outline your development strategy for vonoprazan in NERD? And maybe give us a sense of what the market is, or the commercial opportunity is in this indication.

Question: Joey Stringer - Needham & Company, LLC - Analyst : And last question here on vonoprazan, just a general strategy around a potential partnerships for the asset. Do you plan to keep all the programs in-house and commercialize on your own in EE and H. pylori?

Question: Joey Stringer - Needham & Company, LLC - Analyst : Fantastic. Well, we're out of time for this session. Thank you so much, Terrie, to you and the rest of the Phathom team for participating, and thanks everyone for joining us on the webcast. Have a good day.